Terms: = Prostate cancer AND Neurokinin AND Treatment
6 results:
1. neurokinin-1 receptor drives PKCɑ-AURKA/N-Myc signaling to facilitate the neuroendocrine progression of prostate cancer.
Zhang XW; Li JY; Li L; Hu WQ; Tao Y; Gao WY; Ye ZN; Jia HY; Wang JN; Miao XK; Yang WL; Wang R; Mou LY
Cell Death Dis; 2023 Jun; 14(6):384. PubMed ID: 37385990
[TBL] [Abstract] [Full Text] [Related]
2. The In Vitro Pro-inflammatory Functions of the SP/NK1R System in prostate cancer: a Focus on Nuclear Factor-Kappa B (NF-κB) and Its Pro-inflammatory Target Genes.
Ebrahimi S; Erfani B; Alalikhan A; Ghorbani H; Farzadnia M; Afshari AR; Mashkani B; Hashemy SI
Appl Biochem Biotechnol; 2023 Dec; 195(12):7796-7807. PubMed ID: 37093533
[TBL] [Abstract] [Full Text] [Related]
3. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer treatment.
Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
[TBL] [Abstract] [Full Text] [Related]
4. Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With cancer: A Retrospective Analysis.
Calcanes G; Vacirca JL
J Infus Nurs; 2019; 42(5):260-263. PubMed ID: 31464835
[TBL] [Abstract] [Full Text] [Related]
5. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
Okuyama A; Nakamura F; Higashi T
JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
[TBL] [Abstract] [Full Text] [Related]
6. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract] [Full Text] [Related]